The goal of this Center is to cure cystic fibrosis. Short of that, an intermediate goal is to make the basic science observations required to develop new palliative therapies, with special focus on treating the inflammatory response. To achieve these ends, we developed a Center with strong basic science research, a well-organized, productive clinical research program, and strong interconnections. 37 investigators from 8 departments and 11 integral collaborators gamer >$12 million CF-related external funding, and operate an active training program from the undergraduate to the junior faculty level. Seven cores support this program. The Animal Core provides CF and other special mice. It performs and teaches mouse procedures and creation of infection models. This international core serves many investigators outside Case. The Animal Imaging Core, a new core, will offer SPECT, PET, MRI, conventional radiography, luminescence imaging, radioactive imaging, as well as novel developmental imaging services for mice, and offers a clinical component as well. The Cell Imaging Core provides access to and training in widefield fluorescence microscopy for live cell experiments and deconvolution, as well as facilitated access to confocal microscopes on campus. The Mediator Core offers quality controlled, highly reproducible assays for mediators of interest, most recently, cytokines. In the next grant period we will add Q-RT-PCR, FACS, and other assays that give more information about function, in response to increasing demand. The Statistics Core provides instruction and statistical support for investigators in the Core Center, and has a substantial developmental component. The Clinical Studies Core provides access to well-characterized patients and carefully collected patient samples, and assists with patient based research. The Center supports two feasibility projects, now held by Mark Pagel, Ph.D. (Biomedical Engineering), to develop an MRI imaging particle to detect increased areas of inflammation in lung, and Katrina Goddard, Ph.D.,(Epidemiology and Biostatistics), who will develop new models of haplotype analysis for modifier gene studies. All of these programs are coordinated and supported by the Administrative Core, which provides integrative functions, supports a seminar series, and provides liaison to other institutional Centers and Cores, to the administration, and to NIDDK. The past achievements of the Center predict future success.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK027651-27
Application #
7797509
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (J1))
Program Officer
Mckeon, Catherine T
Project Start
1983-01-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
27
Fiscal Year
2010
Total Cost
$1,122,350
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87

Showing the most recent 10 out of 445 publications